CLINICAL TRIALS AND OBSERVATIONS SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
نویسندگان
چکیده
1Hopital Le Bocage, Dijon, France; 2Hopital Henri Mondor, Créteil, France; 3Centre Georges-Francois Leclerc, Dijon, France; 4Centre François Baclesse, Caen, France; 5Hopital Purpan, Toulouse, France; 6Hopital Saint-Louis, Paris, France; 7Centre Henri Becquerel, Rouen, France; 8CHU Nancy, Vandoeuvre les Nancy, France; 9Hopital Necker, Paris, France; 10Hopital Lyon Sud, Pierre Bénite, France; and 11Hopital Claude Huriez and EA 4481 GRIIOT, Lille 2 University, Lille, France
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis. This investigation prospectively assessed the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-Dglucose (FDG-PET) after two cycles of chemotherapy for prediction of progressionfree survival (PFS) and overall survival (OS) in Hodgkin lymphoma (HL). Seventy-seven consecutive, newly diagnosed patie...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dosedense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20 diffuse large B-cell lymphoma. Patients received a minimum of 3 and a maximum of 6 cycles with 1 ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase 2 trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in untreated...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
This study was set up to demonstrate whether prognostic classification based on the secondary age-adjusted International Prognostic Index (sAA-IPI) for recurring aggressive non-Hodgkin lymphoma (NHL) or the prognostic score for recurring Hodgkin lymphoma (HL) can be improved by including the midtreatment results of fluorine-18-fluorodeoxy-glucose–positron emission tomography (FDG-PET). Clinical...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Whole-Body Positron Emission Tomography Using 18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
A residual mass after treatment of lymphoma is a clinical challenge, because it may represent vital tumor as well as tissue fibrosis. Metabolic imaging by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) offers the advantage of functional tissue characterization that is largely independent of morphologic criteria. We compared 18F-FDG PET to computed tomography (CT) in the pos...
متن کامل